Last reviewed · How we verify
Pivlaz (CLAZOSENTAN)
Pivlaz (generic name: CLAZOSENTAN) is a Small molecule drug developed by Idorsia Pharmaceuticals Japan Ltd. It is currently FDA-approved for Prevention of cerebrovascular spasm.
Pivlaz, also known as clazosentan, is a small molecule. It is being studied in clinical trials for the treatment of aneurysmal subarachnoid hemorrhage.
At a glance
| Generic name | CLAZOSENTAN |
|---|---|
| Sponsor | Idorsia Pharmaceuticals Japan Ltd |
| Target | Endothelin-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Prevention of cerebrovascular spasm
Common side effects
Key clinical trials
- Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain (PHASE3)
- Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping (PHASE3)
- A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function (PHASE1)
- A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan (PHASE1)
- Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (PHASE2)
- Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (PHASE2)
- Clazosentan in Aneurysmal Subarachnoid Hemorrhage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pivlaz CI brief — competitive landscape report
- Pivlaz updates RSS · CI watch RSS
- Idorsia Pharmaceuticals Japan Ltd portfolio CI
Frequently asked questions about Pivlaz
What is Pivlaz?
What is Pivlaz used for?
Who makes Pivlaz?
What is the generic name of Pivlaz?
What development phase is Pivlaz in?
What does Pivlaz target?
Related
- Target: All drugs targeting Endothelin-1 receptor
- Manufacturer: Idorsia Pharmaceuticals Japan Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention of cerebrovascular spasm
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing